CORAL SPRINGS, FL--(Marketwired - Aug 19, 2014) - Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing updates to the marketing plan for their over-the-counter (OTC) pain reliever, Nyloxin®. Nutra Pharma previously announced a commercial campaign that began at the end of June 2014. Additional commercials are being produced as well as ongoing support on a weekly radio campaign.

The newest campaign features weekly interviews with the Company's CEO, Rik J Deitsch, on the radio show Late Night Health ( with host Mark Alyn. Late Night Health covers a myriad of health and wellness topics and presents listeners with the latest breakthroughs, facts, studies, tips secrets and health-oriented information. Topics include dealing with diabetes, obesity and cancer to the latest practices in pain management, stress reduction and preventative health care. The interviews with Mr. Deitsch have focused on the definition of chronic pain, treatment options for pain, the use of the Nyloxin products and the history of the use of cobra venom in traditional and allopathic medicine.

"We are happy to report that the sales of Nyloxin have been steadily increasing over the past few months," said Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "The television commercials, along with the direct marketing by MyNyloxin Distributors, are building brand awareness for the products," he continued. "The new commercials and radio campaign will continue to get the word out about these life-changing products," he concluded.

Nyloxin was also recently featured in a report on CNN's website, "CNN iReport". The article can be found at:

Nyloxin® is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin® is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin® is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.

About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brand Nyloxin®. For additional information about Nutra Pharma, visit: or

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's marketing plan should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact Information:

Nutra Pharma Corp.
Nina Goldstein